Epigenetic drug therapy in the treatment of colorectal cancer

Parizadeh, Seyed Mostafa, Esfehani, Reza Jafarzadeh, Ghandehari, Maryam, Seifi, Sima, Parizadeh, Seyed Mohammad Reza, Moetamani-Ahmadi, Mehrdad, Hassanian, Seyed Mahdi, Khazaei, Majid, Ghayour-Mobarhan, Majid, Ferns, Gordon A and Avan, Amir (2018) Epigenetic drug therapy in the treatment of colorectal cancer. Current Pharmaceutical Design, 24 (23). pp. 2701-2709. ISSN 1381-6128

[img] PDF - Accepted Version
Restricted to SRO admin only until 24 October 2019.

Download (1MB)

Abstract

Colorectal cancer (CRC) is one of the most common cancers with a high rate of morbidity and mortality worldwide. The incidence of CRC is similar in men and women but is distributed uniformly globally. It has been demonstrated that epigenetic alterations which may cause changes in the expression of microRNA, DNA methylation and histone acetylation that results in inheritable modifications in gene expression in colorectal epithelial cells, plays a crucial role in the development of CRC. Recently, targeting epigenetic modification has emerged as a potentially important treatment approach in CRC. The US Food and Drug Association has approved the use of some epigenetic drugs that may be able to inhibit or reverse these alterations and also enhance sensitivity to chemotherapeutic agents and radiotherapy in CRC. In this review we have summarized the recent pre-clinical and clinical trial studies investigating the therapeutic value of using epigenetic drugs as novel therapeutic approach in CRC treatment.
Keywords: epigenetic, colorectal cancer, drug, DNA methylation, histone acetylation

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Brighton and Sussex Medical School
Brighton and Sussex Medical School > Division of Medical Education
Depositing User: Elizabeth Renvoize
Date Deposited: 06 Aug 2018 10:19
Last Modified: 05 Dec 2018 14:32
URI: http://srodev.sussex.ac.uk/id/eprint/77539

View download statistics for this item

📧 Request an update